(−)-18-Methylaminocoronaridine (18-MAC) is a second generation synthetic derivative of ibogaine developed by the research team led by the pharmacologist Stanley D. Glick from the Albany Medical College and the chemist Martin E. Kuehne from the University of Vermont.
See also 2-Methoxyethyl-18-methoxycoronaridinate 18-Methoxycoronaridine Coronaridine Ibogaine Noribogaine Voacangine
References